Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma

Autologous stem-cell transplantation (ASCT) for multiple myeloma continues to confer benefit in the ‘novel agent’ era [1]. However, most patients relapse, risk stratification is inadequate and opti...